SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database

OBJECTIVES: To estimate the health care resource use (HCRU) and costs for patients diagnosed with acromegaly, following treatment with either pegvisomant, a growth hormone receptor antagonist (GHRA); or a somatostatin analogue (SSA). METHODS: De-identified data from Optum’s Clinformatics(TM) Data Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelepouris, Nicky, Emir, Birol, Loftus, Jane, Rubinstein, Emily, King, Donna, McDonald, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551765/
http://dx.doi.org/10.1210/js.2019-SAT-439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551765/
http://dx.doi.org/10.1210/js.2019-SAT-439

Ejemplares similares